CS
PTCT icon

Credit Suisse’s PTC Therapeutics PTCT Stock Holding History

Credit Suisse’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100,000
Closed -$4.5M – 4227
2019
Q2 		$4.5M Buy
+100,000
New +$3.95M ﹤0.01% 1826

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's PTCT Position: Q1 2024 in Review

Credit Suisse held its PTC Therapeutics (PTCT) position steady in Q1 2024 at 83,635 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

Credit Suisse first reported a position in PTCT in Q3 2013 and has held it in 43 quarters since. The position peaked at $72.2M in Q1 2015. 184 funds tracked by Wall St. Rank hold PTCT as of Q1 2024.

  • Credit Suisse held 83,635 shares of PTC Therapeutics worth $2.43M as of Q1 2024.
  • Credit Suisse left its PTC Therapeutics share count unchanged in Q1 2024.
  • PTC Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1725 holding.
  • Credit Suisse first reported a position in PTC Therapeutics in Q3 2013 and has held it in 43 quarters since.
  • Credit Suisse's PTC Therapeutics position peaked at $72.2M in Q1 2015.
  • 184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.